Brokerages Set Solventum Corporation (NYSE:SOLV) Target Price at $83.67

Solventum Corporation (NYSE:SOLV) has been assigned an average rating of “Hold” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $81.9091.

Several equities research analysts have weighed in on SOLV shares. Wells Fargo & Company reduced their price objective on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. BTIG Research reissued a “buy” rating and set a $91.00 target price on shares of Solventum in a research note on Monday, July 13th. Rothschild & Co Redburn started coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Thursday, May 14th. Finally, BMO Capital Markets began coverage on shares of Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company.

Hedge Funds Weigh In On Solventum

Hedge funds and other institutional investors have recently modified their holdings of the business. United Services Automobile Association acquired a new position in shares of Solventum in the first quarter valued at about $239,000. Woodline Partners LP boosted its stake in shares of Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after buying an additional 3,377 shares during the last quarter. Intech Investment Management LLC grew its holdings in Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP grew its holdings in Solventum by 5.8% during the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after acquiring an additional 14,151 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Solventum during the second quarter worth about $766,000.

Solventum Stock Performance

NYSE SOLV opened at $81.36 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The business has a 50-day moving average price of $77.09 and a 200-day moving average price of $74.27. The firm has a market cap of $14.09 billion, a price-to-earnings ratio of 9.97, a price-to-earnings-growth ratio of 1.25 and a beta of 0.66.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the company earned $1.34 EPS. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities research analysts predict that Solventum will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.